Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles Journal of Allergy and Clinical Immunology Year : 2021

Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study

Dates and versions

hal-03843593 , version 1 (08-11-2022)

Identifiers

Cite

Lawrence Eichenfield, Carsten Flohr, Robert Sidbury, Zsuzsanna Szalai, Ryszard Galus, et al.. Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study. Journal of Allergy and Clinical Immunology, 2021, 147 (2), pp.AB146. ⟨10.1016/j.jaci.2020.12.529⟩. ⟨hal-03843593⟩
19 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More